Invention Grant
![Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same](/docs/US/2017-06-13/US09676793B2/abs.jpg.600x600.jpg)
- Patent Title: Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
-
Application No.: US14976713Application Date: 2015-12-21
-
Publication No.: US09676793B2Publication Date: 2017-06-13
- Inventor: Urs Schwitter , Fritz Bliss , Michael Kammerer , Florence Tixeront
- Applicant: Hoffmann-La Roche Inc.
- Applicant Address: US NJ Little Falls
- Assignee: Hoffmann-LaRoche Inc.
- Current Assignee: Hoffmann-LaRoche Inc.
- Current Assignee Address: US NJ Little Falls
- Agency: Mintz Levin Cohn Ferris Glovsky and Popeo, P.C.
- Main IPC: C07D513/04
- IPC: C07D513/04 ; C07C55/12 ; C07C55/08 ; C07C57/15 ; C07C55/14 ; C07C59/06 ; C07C59/185
![Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same](/abs-image/US/2017/06/13/US09676793B2/abs.jpg.150x150.jpg)
Abstract:
Co-crystals of Formula I compounds and their pharmaceutical compositions are novel therapeutics for the treatment of diseases, such as human immunodeficiency virus (HIV) infection, hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection and cancer. The co-crystal are more stable to oxidation and aqueous degradation, have a better pharmacokinetic profile and superior biological activity than the corresponding tosylate salt form of Formula I compound.
Public/Granted literature
Information query
